Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy

Autor: Michael A. Cannarile, Martin Weisser, Wolfgang Jacob, Anna-Maria Jegg, Carola H. Ries, Dominik Rüttinger

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-13 (2017)

Abstract The tumor-permissive and immunosuppressive characteristics of tumor-associated macrophages (TAM) have fueled interest in therapeutically targeting these cells. In this context, the colony-stimulating factor 1 (CSF1)/colony-stimulating factor

Externí odkaz: https://doaj.org/article/d178a458f1254b0b92d2840ec5a6df0e

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade

Autor: Carlos Gomez-Roca, Philippe Cassier, Dmitriy Zamarin, Jean-Pascal Machiels, Jose Luis Perez Gracia, F Stephen Hodi, Alvaro Taus, Maria Martinez Garcia, Valentina Boni, Joseph P Eder, Navid Hafez, Ryan Sullivan, David Mcdermott, Stephane Champiat, Sandrine Aspeslagh, Catherine Terret, Anna-Maria Jegg, Wolfgang Jacob, Michael A Cannarile, Carola Ries, Konstanty Korski, Francesca Michielin, Randolph Christen, Galina Babitzki, Carl Watson, Georgina Meneses-Lorente, Martin Weisser, Dominik Rüttinger, Jean-Pierre Delord, Aurelien Marabelle

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol. 10, no.5, p. e004076 (2022)

BackgroundThis phase 1b study (NCT02323191) evaluated the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of colony-stimulating factor-1 receptor-blocking monoclonal antibody (mAb) emactuzumab in combination with the programmed cel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2c2dc4accf632390ea464a967fc522a
https://pubmed.ncbi.nlm.nih.gov/35577503

ABCL-052 MINDway: A Phase Ib/II Dose Optimization Study to Assess Safety and Pharmacokinetics of Tafasitamab + Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Autor: Richard Greil, Katerina Kopeckova, Luca Arcaini, Aasim Amin, Katrien de Graaf, Anna-Maria Jegg

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 22:S356

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::681e7b49187211f7a65ae05f8df1d3b8
https://doi.org/10.1016/s2152-2650(22)01495-1

Macrophage depletion induces edema through release of matrix-degrading proteases and proteoglycan deposition

Autor: Natascha Rieder, Tatiana V. Petrova, Alejandra González Loyola, Carlos Gomez-Roca, Carl Watson, Martina Schmittnaegel, Anna-Maria Jegg, Vinona Wagner, Vincent Sibaud, Irina Klaman, Michele De Palma, Michael A. Cannarile, Carola Ries, Philippe A. Cassier, Stefan Bissinger, Carina Hage, Ilona-Petra Maser, Verena Brand, Sabine Hoves

Publikováno v: Science translational medicine. 13(598)

Colony-stimulating factor 1 receptor (CSF1R) blockade abates tumor-associated macrophage (TAM) infiltrates and provides marked clinical benefits in diffuse-type tenosynovial giant cell tumors. However, facial edema is a common adverse event associate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ceeb44080fcffebb52e7ecb99015805b
https://pubmed.ncbi.nlm.nih.gov/34135110

Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients

Autor: Carola Ries, Priscila Camillo Teixeira, Dominik Rüttinger, Carlos Gomez-Roca, Wolfgang Jacob, Francesca Michielin, Martin Weisser, Georgina Meneses-Lorente, Jean-Marie Michot, Lauriane Eberst, Anna-Maria Jegg, Irina Klaman, Jean-Pierre Delord, Sabine Hoves, Galina Babitzki, Michael A. Cannarile, Philippe A. Cassier, Jean-Pascal Machiels, Konstanty Korski, Carl Watson, Tara C. Mitchell, Randolph Christen, Gaetan Catala, Dmitriy Zamarin

Publikováno v: Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for ImmunoTherapy of Cancer, Vol. 8, no. 2, p. e001153 [1-12] (2020)

BackgroundThis phase Ib study evaluated the safety, clinical activity, pharmacokinetics, and pharmacodynamics (PD) of emactuzumab (anti-colony stimulating factor 1 receptor monoclonal antibody (mAb)) in combination with selicrelumab (agonistic cluste

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a84d90eef6ef770b34576e40e3415f6
https://doi.org/10.1136/jitc-2020-001153